Sponsored

Chimeric Therapeutics makes headway with its CLTX CAR T therapy; what next?

Source: Mark_Kostich, Shutterstock

Summary

  • Chimeric Therapeutics is progressing well with its Phase 1 CLTX CAR T trial at City of Hope.
  • CLTX CAR T can potentially address the high unmet medical need for recurrent glioblastoma (GBM), given the unique properties demonstrated in preclinical studies.
  • Chimeric is focused on rapid progression towards the registration trial for recurrent GBM.
  • The Company is also assessing the initiation of a Phase 1 basket trial for colorectal cancer, melanoma, prostate cancer, sarcomas, and small cell lung cancer.

Chimeric Therapeutics Limited (ASX:CHM) is a clinical-stage cell therapy company centred around encouraging Chlorotoxin (CLTX) CAR T technology from City of Hope (COH). Currently, the Company is conducting a Phase 1 clinical trial of CLTX CAR T at COH.

CLTX CAR T therapy: first in class

In 2020, CHM licensed the exclusive worldwide rights of CLTX CAR T cell therapy developed at COH Cancer Centre.

CLTX CAR T has an extended life, with a composition of matter intellectual property (IP) profile which expires in 2036. CLTX CAR T utilises Chlorotoxin, a 36-amino acid peptide derived from the toxin of deathstalker scorpion, as its tumour targeting domain.

Image source: CHM Investor Presentation, 18 March 2021

CLTX has a proven human safety profile as it has been employed as an imaging agent. The fact that CLTX can bind to a range of tumours is quite promising and indicates significant therapeutic potential in several solid tumours.

Because of the unique properties demonstrated in preclinical studies, CLTX CAR T has the potential to address the high unmet medical need for effective therapy against recurrent GBM (WHO grade III-IV).

DO READ: Using scorpion venom to treat tumours: A look at Chimeric Therapeutics' CLTX technology

CAR T Cell Therapy in a nutshell

Chimeric Antigen Receptor T (CAR T) Cell Therapy modifies patients’ immune cells (or T-cells) to use directly against their melanoma.

  • In CAR T, patients’ cells are engineered for receptor expression on the cell surface to recognise antigens of cancerous cells.
  • After the administration, CAR T cells identify the antigen targets on malignant cells. The CAR then binds to the cancerous cells.
  • Once CAR T cells bind to the malignant cells, they convey a signal to attack the cancer cells. One single CAR T cell can generate over 10,000 new cells to target and destroy the tumour cells.

Image source: CHM Investor Presentation, 18 March 2021

Increasing unmet medical need in GBM

Almost more than 300,000 patients worldwide are diagnosed with brain and nervous system cancer each year. Given the tremendous unmet medical need for glioblastoma, the new, innovative therapies could offer a valuable treatment for glioblastoma patients.

GBM is the most common and most lethal of brain and nervous system cancer with:

  • The median overall survival of nearly eight months for GBM patients.
  • Almost 5% of GBM patients survive five years.
  • Nearly 38% of patients with GBM survive one-year survival.
  • Only three FDA approved treatments and no standard of care in recurrent GBM.
  • Bevacizumab, the last FDA-approved therapy, did not exhibit overall survival benefit.

DID YOU KNOW: Chimeric Therapeutics (ASX:CHM) onboards new VP to boost oncology pipeline

Phase 1 CLTX CAR T Clinical Study in brief

The Company commenced the dosing of Phase 1 clinical trial in late September 2020 at City of Hope. The trial’s primary objective is to assess the safety of CLTX CAR T cells for patients having MMP2 recurrent GBM and to evaluate the maximum tolerated dose schedule and an advised dosing plan for Phase 2. Here are the details of the trial:

  • Approximately 18-36 patients with recurrent or progressive GBM.
  • Dose escalation of 44 X 106 to 440 X 106 CLTX CAR T cells.
  • CHM is examining two administration methods for the treatment-
    • Single route intratumoral delivery.
    • Dual-route intratumoral and intraventricular delivery.

Image source: CHM Investor Presentation, 18 March 2021

To Know More, Do Read: Chimeric Therapeutics’ (ASX:CHM) Phase 1 CLTX CAR T trial inches ahead

CHM anticipates expanding CLTX CAR T for additional tumours

Based on the available evidence for binding of CLTX in other solid tumours, Chimeric Therapeutics is currently exploring the initiation of a Phase 1 basket trial for colorectal cancer, melanoma, prostate cancer, sarcomas, and small cell lung cancer.

Image source: CHM Investor Presentation, 18 March 2021

Outlook: the way forward

Chimeric Therapeutics is focused on developing its product pipeline with ground-breaking cell therapies in the oncology space.

Chimeric Therapeutics’ plans for the upcoming period:

Image source: CHM Investor Presentation, 18 March 2021

On 14 April 2021, CHM shares were trading 5.172% higher at AU$0.305 (at AEST 03:34 PM).

Comment


Disclaimer

Ad

GET A FREE STOCK REPORT


Top Penny Picks under 20 Cents to Fit Your Pocket! Get Exclusive Report on Penny Stocks For FREE Now.


   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK